What’s in GlycoMimetics, Inc. (GLYC) After Today’s Big Increase?

Investors sentiment increased to 1.32 in Q1 2019. Its up 0.26, from 1.06 in 2018Q4. It improved, as 7 investors sold GlycoMimetics, Inc. shares while 21 reduced holdings. 10 funds opened positions while 27 raised stakes. 44.56 million shares or 0.36% more from 44.40 million shares in 2018Q4 were reported.
Ny State Common Retirement Fund holds 37,300 shares. Jgp Global Gestao De Recursos Ltda has invested 0.05% in GlycoMimetics, Inc. (NASDAQ:GLYC). Proshare Lc owns 18,359 shares for 0% of their portfolio. Morgan Stanley has 6,625 shares for 0% of their portfolio. Price T Rowe Md has 0.01% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 3.42 million shares. 1.10 million were reported by State Street. Geode Capital Management Limited Liability invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Axa holds 0.05% in GlycoMimetics, Inc. (NASDAQ:GLYC) or 925,144 shares. Alps Advsrs owns 0.01% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 104,192 shares. Td Asset Management has 74,310 shares for 0% of their portfolio. Metropolitan Life Insur Ny holds 0% or 6,330 shares. Redmile Limited Liability Company invested in 2.02 million shares. 8,310 are held by Jpmorgan Chase &. Jennison Assoc Limited Liability Co stated it has 0.02% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Deutsche Bancshares Ag reported 0% stake.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) is a huge mover today! The stock increased 4.81% or $0.14 during the last trading session, reaching $3.05. About 1.71M shares traded or 113.04% up from the average. GlycoMimetics, Inc. (NASDAQ:GLYC) has declined 32.63% since August 15, 2018 and is downtrending. It has underperformed by 32.63% the S&P500.
The move comes after 5 months positive chart setup for the $131.74M company. It was reported on Aug, 15 by Barchart.com. We have $3.17 PT which if reached, will make NASDAQ:GLYC worth $5.27M more.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 3 analysts covering GlycoMimetics (NASDAQ:GLYC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. GlycoMimetics has $23 highest and $500 lowest target. $11.33’s average target is 271.48% above currents $3.05 stock price. GlycoMimetics had 9 analyst reports since February 28, 2019 according to SRatingsIntel. SunTrust downgraded the shares of GLYC in report on Monday, August 5 to “Hold” rating. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, August 5 report. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) earned “Buy” rating by H.C. Wainwright on Thursday, March 7.

More notable recent GlycoMimetics, Inc. (NASDAQ:GLYC) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Lower; Tyson Foods Earnings Top Views – Nasdaq” on August 05, 2019, also Schaeffersresearch.com with their article: “GLYC Stock Sliced in Half on Disappointing Drug Data – Schaeffers Research” published on August 05, 2019, Seekingalpha.com published: “GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 02, 2019. More interesting news about GlycoMimetics, Inc. (NASDAQ:GLYC) were released by: Nasdaq.com and their article: “GlycoMimetics Enters Oversold Territory – Nasdaq” published on July 23, 2019 as well as Nasdaq.com‘s news article titled: “Pre-Market Most Active for Aug 5, 2019 : TVIX, GLYC, AMD, QQQ, TQQQ, SQQQ, TOT, BHP, BABA, NIO, NOK, APHA – Nasdaq” with publication date: August 05, 2019.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $131.74 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

GlycoMimetics, Inc. (NASDAQ:GLYC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.